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Abstract
Background: Mycobacterium avium subspecies paratuberculosis (MAP) is a versatile pathogen with a broad host range. Its
association with type-1 diabetes mellitus (T1DM) has been recently proposed. Rapid identification of infectious agents such
as MAP in diabetic patients at the level of clinics might be helpful in deciphering the role of chronic bacterial infection in the
development of autoimmune diseases such as T1DM.
Methodology/Principal Findings: We describe use of an ELISA method to identify live circulating MAP through the
detection of a cell envelope protein, MptD by a specific M13 phage – fMptD. We also used another ELISA format to detect
immune response to MptD peptide. Both the methods were tested with blood plasma obtained from T1DM, type-2 diabetes
(T2DM) patients and non-diabetic controls. Our results demonstrate MptD and fMptD ELISA assays to be accurate and
sensitive to detect MAP bacilli in a large fraction (47.3%) of T1DM patients as compared to non-diabetic controls (12.6%) and
those with confirmed T2DM (7.7%). Comparative analysis of ELISA assays performed here with 3 other MAP antigen
preparations, namely HbHA, Gsd and whole cell MAP lysates confirmed comparable sensitivity of the MptD peptide and the
fMptD based ELISA assays. Moreover, we were successful in demonstrating positive bacterial culture in two of the clinical
specimen derived from T1DM patients.
Conclusions and Significance: The MptD peptide/fMptD based ELISA or similar tests could be suggested as rapid and
specific field level diagnostic tests for the identification of MAP in diabetic patients and for finding the explanations towards
the occurrence of type-1 or type-2 diabetes in the light of an active infectious trigger.
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Introduction
Mycobacterium avium subspecies paratuberculosis (MAP) is one of the
most successful pathogens of human and animals that cause
chronic infection of the intestines followed by immune dysregu-
lation resulting in painful and wasting enteritis in ruminants
(Johne’s disease) [1]. It is also linked to a similar type of enteritis in
humans called Crohn’s disease [2,3]. While the proposed
association of MAP with Crohn’s disease poses a grave proposal
[1,2,3], more alarming is its putative link to the type-1 diabetes
mellitus (T1DM) [4,5,6]. It was long thought that the genetic
susceptibilities, epitope mimicry and endemic bacterial load in the
environment might support the case of an infectious trigger of
T1DM in genetically susceptible individuals [4,7,8]. Evidence of
molecular mimicry of the mycobacterial antigens with self epitopes
has been revealed [9,10,11].
Given that the proposed infectious aetiology of T1DM is getting
ground, a quick detection method that accurately and selectively
identifies MAP within the diabetics is highly desirable to choose
explanations between an ‘infectious’ cause or otherwise for the
development of the diabetes syndrome in different individuals
under different clinical settings. Polymerase chain reaction (PCR)
based detection of the genetic regions of MAP such as the IS900
has been broadly successful and was recently used in diabetes cases
[6] by our group; the method however needs laboratory
infrastructure, and most importantly, it does not selectively detect
PLoS ONE | www.plosone.org 1 February 2009 | Volume 4 | Issue 2 | e4386only the live bacilli. Also, a DNA based diagnostic can not gauge
immune status of the host and the development of an immune
response. These issues recently lead us to the detection in diabetic
patients of anti MAP antibodies [5] by using sensitive antigenic
targets such as HbHA and Gsd proteins. However, these proteins
are also encoded by a wider range of mycobacteria including some
of the saprophytic and environmental mycobacterial organisms
[12]. Further, there could be an underlying possibility of cross
reactivity with the tubercle bacilli in high burden countries and in
BCG vaccinated individuals. In view of these issues, search for
MAP specific protein targets was intensified with some successes
[13]. The identification of mptD gene [14,15] is one such effort
wherein it was projected to be a MAP specific marker of virulence,
expressed only on the surface of the organism and thereby a good
target of the immune system. A phage specific for MptD was
identified which was named as fMptD [15]. We harnessed the
potential of fMptD and the MptD peptide alone for the detection
of MAP in diabetic patients’ blood. This study therefore, entails a
novel phage based ELISA to selectively capture circulating MAP
from the blood plasma with the help of MptD peptide and the
fMptD. MAP cells or their products detected by MptD peptide
and fMptD were further probed with anti human IgG antibodies
(secondary antibodies) to detect MAP specific antibody responses
in patients and controls. We propose this method to be developed
for field level testing of diabetic patients for the presence of MAP;
this can be employed even for high-throughput sero-prevalence
studies in many different clinical case settings involving diabetes
and Crohn’s disease patients.
Results
Detection of antibodies to recombinant HbHA, Gsd and
MAP antigens and whole cell lysate in T1DM and T2DM
patients and controls
A significant difference among the humoral antibody responses to
specific MAP antigens and whole cell lysates, as shown by the T1DM
patients and the non-diabetic controls might strongly signify the
involvement of MAP in T1DM (Figure 1, Table 1). The HbHA
antigen gave strong ELISA titres using a cut-off value of 0.5 as
previously used [6] in 58 % of the T1DM patients and only 5.1% of
the controls (Chi square=44.035, P,0.0001). Also, the Gsd protein
revealed significant differences in ELISA titres of the diabetic (45.6%
positivity) and control individuals (15.2% positivity) at the cut off
value of 0.4 (Chi square=13.74, P,0.0002) [5]. The cell lysate also
revealed significant titres in 70% of the T1DM patients as compared
to controls (7.6%) at a cut-off of 0.5 (Chi square=54.49, P,0.0001)
[5]. As expected, none of the results corresponding to all the three
antigen preparations were comparable to the observations made for
T2DM patients confirming our published data [16] (data not shown).
Detection of MAP by MptD-peptide and fMptD based
immuno assays in T1DM and T2DM cases and controls
The MptD-peptide and the fMptD phage assay results were
extremely significant and supportive of the infectious involvement
of MAP in T1DM (Fig. 1). Twenty seven out of 57 T1DM plasma
samples were above the cut off of 0.4 [as previously used for the
other proteins [5]] when screened against fMptD, whereas, only
Figure 1. A. Evaluation of the reactivity of plasma samples representing 57 T1DM patients, 57 T2DM patients and 79 healthy controls against the
fMptD (phage). B. Reactivity of plasma samples obtained from 57 T1DM patients, 57 T2DM patients and 79 healthy controls against the MptD peptide
(B). Data are presented as values of OD405 observed following ELISA as described in the text. The median value for each group is indicated by a dark
solid horizontal line. Data shown are from a representative experiment out of the three performed.
doi:10.1371/journal.pone.0004386.g001
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T1DM Patients sex Year of birth Year of diagnosis fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
01 F 1986 2000 +++2 +
02 F 1976 1996 +++++
03 F 1979 1985 2 ++2 +
04 M 1971 1982 222++
05 M 1966 1989 2222+
06 F 1969 1997 + 2 + 2 +
07 M 1970 1996 22+ 2 +
08 M 1981 2005 +++++
09 M 1977 1996 22+ 2 +
10 F 1970 1998 +++2 +
11 F 1972 1985 +++2 +
12 F 1970 1970 22+ 2 +
13 M 1980 1989 +++++
14 F 1976 1979 +++++
15 M 1967 2005 2222+
16 M 1989 2003 2222+
17 M 1969 - 2222+
18 F 1967 2005 2222+
19 F 1976 1999 + 2 + 2 +
20 F 1981 2002 +++++
21 F 1971 1983 + 2 + 2 +
22 F 1967 1996 2 + 22+
23 F - 1997 +++++
24 F 1973 1999 2222+
25 M 1966 1996 + 2 +++
26 F 1971 1994 2 + 222
27 M - 1989 +++2 +
28 F 1968 2002 + 222+
29 F 1970 1988 +++++
30 M 1975 1989 22+ 22
31 M - 1983 22222
32 F 1974 1984 2222+
33 F 1974 2002 +++++
34 M 1969 1994 22222
35 M 1974 1995 22222
36 M 1975 1976 + 222+
37 M 1981 1994 + 2222
38 M 1975 1988 +++++
39 F 1969 1974 + 2 ++2
40 M 1973 1989 22+++
41 M - 1989 22+++
42 M 1966 1978 + 22+ 2
43 M 1913 - 22+++
44 M 1971 - 22+++
45 M 1980 2004 +++++
46 M 1974 1995 222+ 2
47 M 1979 2000 + 2 +++
48 F 1974 1983 222+ 2
49 F 1984 1989 22++2
50 M 1963 1989 22222
Linking MAP to Type-1 Diabetes
PLoS ONE | www.plosone.org 3 February 2009 | Volume 4 | Issue 2 | e438610 out of 79 were positive among the controls (Chi
square=18.428, P,0.0001). On the other hand, 17 out of 57
T1DM plasma samples were above the cut off when the MptD
peptide was used in ELISA, whereas, only 2 out of 79 were
positive among the healthy controls (Chi square=17.899,
P,0.0001). Significance of the assays was maintained when the
cut-off (0.4) was calculated as 4 SD different from the mean O. D.
result obtained from the negative controls (Chi square=7.713
with 1 degree of freedom; the two-tailed P=0.0055).
The results were again not verifiable in case of T2DM as shown
above for the MAP antigen based ELISA results (Fig. 1, Table 2).
In fact, only 4 among 57 T2DM patients were above the cut off
when the phage was used in ELISA; whereas, 10 control patients
were positive (Chi square=0.279, P=0.5971). Among the 57
T2DM patients, MptD based ELISA test confirmed 4 plasma read
as positive; whereas, it only detected 2 positives out of the 79
controls (Chi square=0.735, P=0.3914).
Overall, the ELISA results based based on fMptD were
comparable in performance and sensitivity and were superior in
specificity as compared to the three antigen preparations (Figure 1,
Table 1).
The fMptD assay gave strong ELISA values (cut-off value 0.4) in
47.3 % of the T1DM patients and only 12.6% of the controls. As
expected the phage assay did not detect any significant antibody
values in T2DM patients (Table 2) (7% positivity) and in controls
(12.6%) (Table 3).
The MptD-peptide confirmed the values obtained with the
fMptD assay although with a light decrease counterbalanced by
lower background levels in the controls. In particular with a cut-off
value of 0.4, 29.8% of the T1DM patients tested positive and only
2.5% of the controls were found above the cut off titres (Table 3).
As compared to the fMptD assay, the peptide assay did not find
any significant values in T2DM patients (Table 2).
We do not believe that the background associated with other
mycobacterial loads might have affected (or augmented) our
results. This is because the tuberculosis status of all our subjects
and controls was definitely negative. Also, since the fMptD and the
MptD assays are based on blood plasma, we seemingly assayed
presence of live bacilli (and their products) in the blood of T1DM
patients, which was certainly the MAP, because from two out of
ten T1DM inoculated samples presence of MAP cells was
confirmed by growth as well as by amplification of IS900 as a
MAP specific target [6,18]. Another important reason to argue in
favour of the specificity of the test is that it is specific to a
mycobacterial envelope protein MptD, which is uniquely present
only in MAP [14,15]. Moreover, when the phage alone (not
codifying for the MptD protein) was used as a control, the results
revealed no statistical difference between T1DM and control
plasma as well as T2DM and control plasma (data not shown).
Isolation of MAP from T1DM plasma samples
Ziehl-Neelsen staining performed on the T1DM, T2DM and
control samples was negative for the presence of any acid fast cells.
However, after 14 weeks MGIT instrument detected growth in 2
(n. 23 and 27) of the 10 inoculated T1DM samples but none in the
other samples. An aliquot of the MGIT culture was then
inoculated onto 7H10 solid medium plus mycobactin J and after
6 weeks small colonies were observed. None of the other samples
were tested positive for bacterial growth after 6 months and then
they were discarded. Samples 23 and 27 were also both positive for
all the serological tests used except for Gsd which was not
recognized by the serum of patient no. 27.
The 2 isolates were not able to grow in 7H10 without the
addition of Mycobactin J and they tested positive for IS900 (MAP
species specific) PCR previously used [6,18]. Sequence of the
amplicon confirmed IS900 identity (data not shown).
Discussion
The Mediterranean island of Sardinia is highly endemic for the
presence of MAP infection in sheep [3,17] concurrently with a
very high number of MAP positive Crohn’s disease patients
[3,17,18]. Infected domestic animals such as sheep and cattle
excrete huge numbers of MAP into the environment where their
survival and persistence particularly within the protists is well
established [1,19]. Environmental cycling involves spread of MAP
through wildlife such as rabbits and re-infection of livestock also
through deposition of extracted slurry from water treatment plants
back onto the farmland [1,19]. Further, there is a potential for the
dispersal of these pathogens via aerosols and for the cycling of
human strains of MAP within human populations [19]. Passage of
these robust, versatile organisms within such cycles extends the
opportunity for their evolution and augmentation of pathogenicity.
Humans are exposed to MAP through the environment and after
the community milk supplies get contaminated [1,2]. Influenced
by the phenotype and genetic lineage of the organism the outcome
of such exposure may be the acquisition of some natural resistance.
In other cases it may lead to persistent colonization which, in the
presence of particular virulence determinants coupled with host
susceptibility, may eventually lead to the development of chronic
inflammation of the intestines with features typical of paucimi-
crobial Johne’s disease in animals [2,3]. The reliable scientific
evidence for the involvement of strains of MAP in the causation of
Crohn’s disease has become very strong in recent times [2,3,19].
T1DM Patients sex Year of birth Year of diagnosis fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
51 M 1964 1986 22++2
52 M - 1992 + 2 +++
53 F 1948 1979 + 22+ 2
54 F 1968 - 22222
55 F 1965 1967 22222
56 F 1968 1981 + 2 +++
57 F 1960 1966 22222
Total 27 17 33 26 40
doi:10.1371/journal.pone.0004386.t001
Table 1. cont.
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T2DM Patients sex Year of birth Year of diagnosis fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
01B M 1946 2002 2222 2
02B F 1942 1992 2222 2
03B M 1942 2001 2222 2
04B M 1927 1989 2222 2
05B M 1934 2003 2222 2
06B M 1946 2002 2222 2
07B F 1958 2003 222+ 2
08B M 1955 2005 2222 2
09B M 1933 2001 2222 2
10B F 1936 1996 ++2 + 2
11B F 1968 - 2222 2
12B F 1932 1991 2222 2
13B M 1951 1998 2222 2
14B M 1946 1994 2222 2
15B F 1931 2000 22+ 2 +
16B M 1952 1992 2222 2
17B M 1937 1993 2222 2
18B M 1943 2006 2222 2
19B M 1942 1998 2222 2
20B F 1939 2005 2222 2
21B M 1933 2004 222+ 2
22B M 1945 2001 2222 2
23B F 1948 1992 2222 2
24B M 1940 1986 ++2 + 2
25B M 1951 1996 2222 2
26B M 1942 - 2222 2
27B M 1932 2001 2222 2
28B F 1934 2001 2222 2
29B F 1932 - 2222 2
30B F 1944 - 2222 2
31B M 1939 2000 2222 2
32B M 1942 - 2222 2
33B F 1943 - 2222 2
34B M 1943 - 2222 2
35B F 1935 1992 2222 +
36B M 1928 - 2222 2
37B M 1946 1990 2222 2
38B M 1938 1998 2222 +
39B M 1934 2004 2222 2
40B M 1930 2003 2222 2
41B M 1930 2000 2222 2
42B F 1955 2002 2222 2
43B F 1959 2005 ++2 ++
44B M 1939 1993 2222 2
45B M 1938 2000 2222 2
46B M 1936 2003 2222 2
47B M 1948 2005 2222 2
48B F 1941 2000 2222 2
49B F 1944 1997 2222 2
50B M 1955 2004 2222 2
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others, are on the list of additional associated conditions [20]. The
MAP problem presents as a covert, slowly evolving epidemic
whose progression with all its threats involving humans and farm
animals, will continue until the true nature of the threat is at last
unraveled. The well-argued case of T1DM [5] is just another facet
of this threat which is looming large.
T1DM develops as a consequence of autoimmune responses
that lead to the destruction of insulin producing beta cells of the
pancreas [7]. Also, there has been a long speculation over the
involvement of an infectious trigger underlying such autoimmune
responses [4,9,11,21,22,23,24]. Recent evidences originating from
the previous studies from our group associate MAP infection to the
T1DM through PCR and ELISA based qualitative detection [5,6].
There is however, the need to prove presence of live, circulating
bacteria in diabetic patients that might potentiate the idea of a
persistent infection existing in such patients as a first step to
confirm involvement of MAP in diabetes. It was previously shown
in case of M. tuberculosis that they often escape to the peripheral
blood in case of invasive pulmonary tuberculosis [25]. Also, MAP
were successfully cultured from the blood of Crohn’s disease
patients [2]. Circulation of MAP in diabetics was speculated [11]
based on PCR assay, but, PCR could also detect degraded DNA
as the products of lysed bacilli [6]. The immunogenic proteins of
diagnostic value, namely the HbHA and Gsd that we successfully
used to demonstrate anti-MAP humoral responses in the past
suffer up to some extent because they are not MAP specific in a
strict sense [5] and again they may not be indicative of an active
infection. We therefore, sought to develop a method that was
competent to specifically trap live MAP bacilli from blood since
culture of MAP is quite tedious and difficult and often bacillary
load in the samples in the absence of an invasive disease like
Crohn’s may not be sufficient to generate optimum growth in
culture media [2,3,26]. Our fair choice therefore, was limited to a
phage based detection and we narrowed down our option to a
MAP specific protein MptD, for which a specific phage was
fortunately available [15]. The phage fMptD binds on the surface
of MAP and its target, the MptD is already an established
virulence factor that expressed during active infection of the
natural host [14,27]. Recently it was validated as a diagnostic
target for the detection of MAP in a large number of bulk milk
samples obtained from MAP infected herds [15].
Two different types of ELISA were performed – first, by fixing
the phage to the plates and testing against the plasma of patients
and controls. Here, if MAP was present in the plasma it was
binding to the phage through MptD. Given the fact that in the
plasma of patients (where MAP is present), antibodies against
MAP shall be present and these antibodies are likely to bind to the
phage-trapped MAP cells. In this case, secondary anti human IgG
conjugated with alkaline phosphatase shall bind to the anti MAP
previously bound. So the signal was amplified after adding the
enzyme substrate. In the second format we coated the plates first
with the plasma of patients and controls and then added fMptD.
The fMptD was probed by an enzyme conjugated anti M13
antibody. In this case we obtained the same results but with a
lower sensitivity; this may be because we are revealing only one
target (MptD), whereas, in the first case although the binding was
MptD specific the results were indicative of an amplified signal
from different anti MAP antibodies present in the plasma of
positive patients. Both the formats (fMptD and MptD ELISA) thus
supported our hypothesis that MAP is circulating in the blood of
T1DM patients.
The isolation of two MAP strains out of ten inoculated fresh
blood samples is extremely important. It supports the results
obtained by the MptD ELISA confirming our hypothesis that live
MAP are circulating within the blood stream of T1DM patients.
Furthermore, the T1DM patients from whom the MAP strains
were isolated (23 and 27), were also both positive for all the
serological tests used except for Gsd (antibodies for which were not
abundant in the plasma of patient no. 27); this is a further
indication of the accuracy of the tests that we employed.
The fact that the phage performed betterin the T1DM patients is
counterbalanced bythe relativelyhigh levelofpositivityfoundinthe
controls. Perhaps a relative lack of specificity for the phage assay
(instead of an increased sensitivity of the phage assay), could be the
alternative explanation for the higher response rates in all groups
based on this assay. However, the MptD peptide response was
statistically significant in the T1DM patients and it was not
recognized in the controls (as low as in the 2% of people) confirming
its high specificity. Moreover, when native M13 phage was used to
investigate if the phage alone was recognized in T1DM, T2DM and
controls, no statistically-significant results were found.
One of important observations that we recorded during this
study was the absence of any significant association between MAP
and the T2DM. T2DM had previously been linked to mycobac-
teria as early as in 1954 by Toba [28] and afterwards in 1964 [29]
and recently by Broxmeyer et al. [30]. We here demonstrate that
T2DM patients do not have significant levels of anti MAP
antibodies in contrast to their T1DM counterparts. This seemingly
hints at the possibility where the involvement of immune
dysregulation (as seen in case of Crohn’s disease and T1DM) in
T2DM becomes irrelevant as a possible mechanism.
T2DM Patients sex Year of birth Year of diagnosis fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
51B M 1952 1994 2222 2
52B M 1946 - 2222 2
53B F. 1935 - + 222 2
54B M 1942 1989 2 + 22 2
55B F 1948 2001 2222 2
56B F 1946 - 2222 2
57B F 1953 2003 2222 2
Total 4 4 1 5 4
doi:10.1371/journal.pone.0004386.t002
Table 2. cont.
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Controls sex Year of birth fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
01C F 1974 22 222
02C F 1964 22 222
03C M 1982 22 222
04C F 1957 22 222
05C M 1977 22 222
06C F 1978 22 222
07C F 1969 22 222
08C M 1950 22 222
09C F 1947 22 22+
10C M 1962 22 222
11C M 1962 22 222
12C M 1958 22 222
13C M 1970 22 222
14C M 1974 22 222
15C M 1946 22 222
16C M 1946 22 222
17C M 1946 22 222
18C F 1947 22 222
19C M 1964 22 222
20C F 1973 22 222
21C F 1982 22 222
22C M 1950 22 222
23C M 1962 22 222
24C F 1979 22 222
25C M 1962 22 222
26C M 1962 + 2 222
27C M 1970 22 222
28C M 1959 22 222
29C F 1950 22 222
30C M 1977 22 222
31C M 1970 ++ +++
32C M 1968 22 222
33C M 1979 22 222
34C F 1972 + 2 222
35C F 1986 22 222
36C M 1986 22 222
37C M 1962 22 222
38C M 1968 22 2+ 2
39C F 1961 22 2+ 2
40C M 1988 22 222
41C M 1971 22 222
42C F 1956 22 222
43C M 1983 + 22 ++
44C M 1965 22 222
45C M 1946 + 22 + 2
46C F 1974 22 2++
47C M 1978 22 222
48C M 1954 22 222
49C M 1983 + 2 222
50C M 1984 + 22 2 +
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clinical phenotype, some concerns might originate from the
observation of a slight positivity of MAP shown up in the control
samples (as they were not 100% negative to the presence of anti
MAP antibodies). We believe that fewer MAP positive control
samples could represent subclinical cases of the past foci of MAP
or they are genetically resistant to diabetes or Crohn’s despite the
fact that they have a defined load of MAP in their circulation.
As far as the application of the test is concerned, especially the
MptD-based ELISA, we are confident that such tests hold
significant potential for use in clinical diagnostics towards the
species specific identification of MAP in T1DM and the Crohn’s
disease. Further, these tests might be used in equal success in the
veterinary arena because there is no ‘gold standard’ herd level
screening tool available for Johne’s disease.
Materials and Methods
Patient and control plasma samples
A total of 136 participants comprising of 57 with T1DM and 79
healthy controls were tested for the presence of MAP specific
antibodies. The healthy controls were randomly selected from the
blood donors attending the University Hospital of Sassari. An
equal number of type-2 diabetic (T2DM) patients (n=57) were
tested as compared to the same control individuals for the MptD
peptide, fMptD and MAP antigen ELISAs. Written informed
consents from patients and controls including other necessary
clearances were obtained before blood samples were drawn.
Institutional Review Board of the University of Sassari approved
the study. In diabetic patients, clinical diagnoses for T1DM or
T2DM were already confirmed including biochemical parameters
such as glucose and insulin levels analyzed. Five millilitres of
peripheral blood was drawn in heparinized vacutainer tubes from
patients and controls and was centrifuged at low speed to separate
plasma for use in ELISA. The same was aliquoted and stored
frozen at 220uC for short-term storage (,6 months) and 280uC
for long term storage (.6 months).
Isolation of MAP after plasma inoculation into
Mycobacterial selective media
Ten fresh samples from T1DM patients (from nos. 20 to 29), 10
samples from T2DM patients (from no. 20 to 29) and 10 control
Controls sex Year of birth fMptD (0.4) MptD (0.4) HbHA (0.5) Gsd (0.4) MAP lysate (0.5)
51C F 1979 22 222
52C M 1972 22 2+ 2
53C M 1986 + 22 ++
54C M 1979 22 2+ 2
55C M 1978 22 222
56C M 1984 22 222
57C F 1965 22 222
58C F 1969 22 222
59C M 1974 22 222
60C M 1979 22 222
61C M 1963 + 2 222
62C M 1966 22 222
63C F 1978 22 222
64C F 1979 22 222
65C M 1958 22 222
66C M 1981 22 ++2
67C M 1978 22 + 22
68C M 1965 22 222
69C M 1975 + 2 ++2
70C M 1958 22 2+ 2
71C M 1950 22 222
72C F 1968 22 222
73C M 1983 22 222
74C M 1976 22 222
75C F 1974 22 222
76C M 1976 22 222
77C M 1980 2 + 222
78C M 1983 22 222
79C M 1964 22 222
total 10 2 4 12 6
doi:10.1371/journal.pone.0004386.t003
Table 3. cont.
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of acid-fast bacilli after Ziehl-Neelsen staining of PMBC smears
prepared from plasma. The samples were then inoculated into the
tubes within a MGIT 960 non-radioactive culture system (Becton
Dickinson) where Mycobactin J and Egg yolk emulsion (20 ml) had
previously been added to the 7H10 medium (Becton Dickinson).
The media were then incubated into the MGIT instrument until
growth was detected or at 37uC in a 5% CO2 atmosphere for up to
6 months.
MAP IS900 amplification
Mycobacterial DNA extraction and PCR to detect IS900 was
performed as previously published [6,18].
ELISA with fMptD, MptD peptide and other MAP antigen
(s) - HbHA, Gsd and MAP whole cell lysate
M13 phage fMptD, previously isolated [15] from the PhD-12
phage display library and was found to be specific for the MAP
envelope protein MptD was obtained from the laboratory of
Gerald F. Gerlach (University of Vet. Medicine, Hanover,
Germany). MptD peptide (GKNHHHQHHRPQ) was synthe-
sized by Brain Research Centre, UBC, 2211 Wesbrook Mall,
Vancouver, BC, Canada V6T 2B5.
Recombinant proteins HbHA and Gsd and the whole cell lysate
preparations were produced in our laboratories exactly as
described previously [5,12]. fMptD and MptD-peptide based
ELISA were performed in 96-well microtitre plates (Maxisorp;
Nunc-Immunoplate, Roskilde, Denmark). Each well was coated
either with 10
8 PFU of fMptD in carbonate bicarbonate buffer
(Sigma-Aldrich) or, when MptD peptide was used, 50 ml of MptD
peptide at the concentration of 5 mg/ml was spotted in each well
and the microtitre plates were incubated at 4uC overnight. Next
day, excess (of untithered) phage was washed out and each well
was filled with 200 ml of blocking buffer (5% non-fat dried milk,
Sigma-Aldrich) and the microtitre plates were incubated for 1
hour at room temperature (RT). After washing with 200 mlo f
PBS-T (PBS-0.05% Tween 20) for two times, 100 ml of diluted test
plasma sample (1:100 in PBS-T) was added to each well and
incubated for 2 hours at room temperature. Plates were then
washed five times with PBS-T and incubated for 1 hour with
100 ml of anti Human IgG-alkaline phosphatase antibody (Sigma–
Aldrich) diluted to 1:1000 in PBS-T. Five rounds of washings were
performed and 200 mlo fp-nitrophenylphosphate (Sigma–Aldrich)
was added to each well and used as substrate for alkaline
phosphatase (AP) enzyme. As the yellow color developed, plates
were read at 405nm by using the VERSA Tunable Max
microplate reader (Molecular Devices, USA). Phage Immuno
Assay (fIA) and MptD-peptide immunoassay were also performed
by using blood plasma as substrate to coat the microtitre plates
(sensitivity obtained was lower than using the phage as a substrate,
data not shown). However, the protocol using the MptD-peptide
or the phage as a substrate as described above was found to be
easy and efficient and was therefore, adopted as such and
recommended for all the assays.
ELISA was also performed using the M13 phage as the only
substrate against plasma of T1DM, T2DM patients and controls
and no cross reaction was observed. ELISA with MAP antigens,
HbHA, Gsd and whole cell lysates was performed as described
previously [5]. Optical density values were compared with those
obtained with MptD-peptide and fMptD assays above.
Statistical analysis
All the ELISA, MptD-peptide and fIA experiments were
performed in replicates and the results were expressed as
means6the standard error (SE). All the values were compared
using Chi-Square test of significance with Yate’s corrections. All
the values were also compared by a two-tailed Student’s t test and
considered significant if the P values were ,0.05. P values were
calculated using the online Graph Pad scientific calculator (http://
www.graphpad.com_quickcalcs_ttest1.cfm).
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